Further evidence was provided by another study [84] that used PBMCs of 29 MM patients before and after pembrolizumab treatment to identify pharmacodynamic changes in circulating exhausted CD8+ T cells. The gene discussed is CD8A; the disease is Miyoshi myopathy.